CD110 一抗-CD110 Primary antibody代理/參數(shù)/廠家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > 一抗

購買方式: Promab中國區(qū)現(xiàn)貨中心已經建立，95%產品中國有現(xiàn)貨庫存。銀行轉賬、電匯、支票、現(xiàn)金，在線支付寶及網銀支付，或直接與我們電話聯(lián)系。本公司所有產品僅供科研使用，不用于臨床診斷。

背景資料: In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

免疫原: Purified recombinant fragment of human CD110 (AA: extra 26-175) expressed in E. Coli.

其他: ProMab 生物技術公司通過整合生物信息學、分子生物學、蛋白質表達、純化技術、基因克隆、微生物學和免疫學，利用新型高通量技術開發(fā)重組蛋白、抗體和工程細胞系并將其商業(yè)化。專注于免疫治療領域，特別是 CAR-T/NK 細胞技術。ProMab 還開發(fā)了一種新型的 mRNA 脂質納米顆粒（mRNA-LNP）平臺，用于即用型試劑和定制研究服務，以推進現(xiàn)有產品并擴展到更多的研究領域。